Filamin-A Increases the Stability and Plasma Membrane Expression of Polycystin-2

Qian Wang1, Wang Zheng1, Zuocheng Wang1, JungWoo Yang1, Shaimaa Hussein1, Jingfeng Tang2,1*, Xing-Zhen Chen2,1*  

1 Membrane Protein Disease Research Group, Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada, 2 Membrane Protein Disease and Cancer Research Center, Hubei University of Technology, Wuhan, China

Abstract

Polycystin-2 (PC2), encoded by the PKD2 gene, is mutated in ~15% of autosomal dominant polycystic kidney disease. Filamins are actin-binding proteins implicated in scaffolding and membrane stabilization. Here we studied the effects of filamin on PC2 stability using filamin-deficient human melanoma M2, filamin-A (FLNA)-replete A7, HEK293 and IMCD cells together with FLNA siRNA/shRNA knockdown (KD). We found that the presence of FLNA is associated with higher total and plasma membrane PC2 protein expression. Western blotting analysis in combination with FLNA KD showed that FLNA in A7 cells represses PC2 degradation, prolonging the half-life from 2.3 to 4.4 hours. By co-immunoprecipitation and Far Western blotting we found that the FLNA C-terminus (FLNAC) reduces the FLNA-PC2 binding and PC2 expression, presumably through competing with FLNA for binding PC2. We further found that FLNA mediates PC2 binding with actin through forming complex PC2-FLNA-actin. FLNAC acted as a blocking peptide and disrupted the link of PC2 with actin through disrupting the PC2-FLNA-actin complex. Finally, we demonstrated that the physical interaction of PC2-FLNA is Ca-dependent. Taken together, our current study indicates that FLNA anchors PC2 to the actin cytoskeleton through complex PC2-FLNA-actin to reduce degradation and increase stability, and possibly regulate PC2 function in a Ca-dependent manner.

Introduction

Polycystin-2 (PC2 or TRPP2) belongs to the transient receptor potential polycystin (TRPP) subfamily of TRP channels. PC2 is a 968 amino-acid (aa) integral membrane protein with six transmembrane domains and intracellularly localized N- and C-termini. Encoded by the PKD2 gene, PC2 is a Ca-permeable cation channel [1] mainly located on the endoplasmic reticulum (ER) membrane [2], but is also present in the primary cilium [3,4] and plasma membrane (PM) [5]. PC2 membrane targeting is regulated by several factors, such as PC1, phosphofurin acidic cluster sorting proteins and intracellular calcium release [6–9]. Mutations in PKD2 account for 10–15% of the autosomal dominant polycystic kidney disease (ADPKD) [1], a
prominent inherited disorder that affects 12.5 million people worldwide. ADPKD is characterized by formation of cysts in kidneys, and to a less extent in liver and pancreas. At the cellular level, ADPKD is associated with elevated cell proliferation, apoptosis, and de-differentiation [10–12]. Until now, the underlying mechanisms of cyst formation have remained ill-defined and no effective therapy has been developed. Previously, we found that PC2 down-regulates cell proliferation via promoting PERK-dependent phosphorylation of eukaryotic initiation factor eIF2α [13]. Mice with either loss- or gain-of-function of PC2 are cystogenic [14,15]. Therefore, it seems that PC2 cellular level has to be regulated within a narrow range.

Filamin-A (FLNA), the first non-muscle actin filament cross-linking protein, was identified in 1975 [16]. The filamin protein family comprises three members, FLNA, filamin-B and-C (FLNC) which share 60–80% sequence homology, of which FLNA is the most abundant and widely distributed [17]. Filamins contain a spectrin-related domain in the N-terminus that directly binds actin and is followed by 24 β-sheet repeats [17,18]. The most C-terminal repeat #24 mediates formation of a homodimer of flexible V-shaped structure that acts as ‘a molecular leaf spring’ to facilitate cross-linking of actin filaments [19]. By cross-linking cortical actin, filamins give cells a dynamic three-dimensional structure. They also interact with a large number of proteins of great functional diversity, indicating that they are versatile scaffolding proteins. Over 90 filamin-interacting partners have so far been identified, including channels, receptors, intracellular signaling molecules, and even transcription factors [20]. Recently, we reported that filamins interact with the epithelial sodium channel (ENaC) on the surface membrane for both structural purposes and functional regulation [21]. The presence of this extensive array of associated proteins may account in part for the fact that mutations in human filamin genes result in a wide range of cell and tissue anomalies, including bone anomalies, periventricular heterotopias, aortic dissection and aneurysm [22–24].

Connections between PC2 and cytoskeleton proteins have been established by several studies. Among PC2-interacting partners identified so far, half are cytoskeleton or cytoskeleton-associated proteins [25]. In 2005, we found that α-actinin, an actin-binding protein important in cytoskeleton organization, cell adhesion, proliferation and migration, interacts with both the intracellular N- and C-termini of PC2 and substantially stimulated its channel function [26]. PC2 channel function is modulated by dynamic changes in actin filament organization in the apical membrane of human syncytiotrophoblast, which is the most apical epithelial barrier that covers the villous tree of human placenta [27]. Further studies suggested that cytoskeleton proteins are likely to mediate the regulation of PC2 channel function by physical forces such as hydrostatic and osmotic pressure in human syncytiotrophoblast [28]. In mitotic spindles of dividing cells PC2 interacts and co-localizes with mDia1, a member of the RhoA GTPase-binding formin homology protein family that participates in cytoskeletal organization [9]. Recently, we demonstrated that C-terminus of filamins directly bind to both the intracellular N- and C-termini of PC2, and that FLNA substantially inhibits PC2 channel activity in a lipid bilayer reconstitution system [21].

In the present study, we explored the role of FLNA in regulating PC2 stability and degradation, using mammalian cultured cells in combination with 35S pulse labeling, Western blotting (WB), co-immunoprecipitation (co-IP), cell surface biotinylation, and gene over-expression/knockdown (KD). We also examined the Ca-dependence of the PC2-FLNA binding.

**Materials and Methods**

**Antibodies**

PC2 (H-280), GFP (B-2), FLNA (E-3), FLNA (H-300), β-actin (C4), Na/K ATPase (H-300) and HSP60 (H-1) antibodies were purchased from Santa Cruz Biotech (Santa Cruz, Dallas, TX,
USA). PC2 (1A11) mouse polyclonal antibody [26,29] and PC2 (H-280) was used to detect native PC2. Antibody E-3 against the N-terminus of FLNA was used to detect full-length FLNA while antibody H-300 was used to detect both the full length and C-terminus of FLNA (FLNAC, aa 2150–2647). Goat anti-GFP (EU4) was purchased from Eusera (Eusera, Edmonton, AB, Canada). Secondary antibodies were purchased from GE Healthcare (Baie d’Urfé, QC, Canada).

Cell lines and transfection

M2 and A7 PC2 stable cell lines, as previously described [21], were maintained with hygromycin (100 μg/ml) (M2) or hygromycin plus G418 (300 μg/ml) (A7) (Invitrogen Canada, Burlington, ON, Canada). Full length human FLNA plasmid pcDNA3-myc-FLNA (ID 8982) was purchased from Addgene (Addgene, Cambridge, MA, USA). FLNA shRNA and the corresponding empty vector p/PUR/U6 as a negative control were generous gifts of Dr. Z. Shen (Cancer Institute of New Jersey, New Brunswick, NJ, USA). Briefly, HeLa and A7 cells were transfected with either the empty vector or FLNA shRNA using the Lipofectamine 2000 reagent (Invitrogen Canada) according to the manufacturer’s instructions. After 48 hours (hr) of transfection, 5 μg/ml of puromycin (Invitrogen Canada) was added to the medium for selection of FLNA stable KD cells. FLNA siRNA pairs 5601 (5’-CCCAUGGAGUAGUAACAATT-3’ and 5’-UUGUUCACUACUCAUGGTTG-3’), 7116 (5’-CAGAAAUUGACCAAGAUAATT-3’ and 5’-UUAAUCUUGGUCAAUUUCUGTG-3’), and 371 (5’-GGAAGAAGAUCCAGCA GAATT-3’ and 5’UUCUGCUGGAUCUUCCAC-3’), were ordered from GenePharma (GenePharma, Shanghai, China). FLNA siRNA, or control siRNA were transfected into HeLa, human embryonic kidney (HEK293) and mouse inner medullary collecting duct (IMCD) cells using HiPerFect Reagent (Qiagen, Hilden, Germany) according to the manufacturer’s instructions (siRNA final concentration: 20 nM). Cells were transfected for a second time after 24 hr. The efficiency of shRNA and siRNA KD was assessed by immunoblotting (IB). Transient transfection with previously described pEGFPC2 plasmids (with GFP tag) harboring PC2, the C-terminus of PC2 (PC2C, aa 682–968), the N-terminus of PC2 (PC2N, aa 1–215) or His-FLNAC [21] was also performed using Lipofectamine 2000 and the expression was assessed 48 hr after transfection. For IMCD and M2 cells, a second transfection was performed 24 hr after the first transfection to increase transfection efficiency. Cells were harvested 72 hr after the first transfection.

35S pulse labeling

35S pulse labeling assay was carried out to study the effect of FLNA on PC2 synthesis. Equal number of M2 and A7 cells either stably or transiently expressing GFP-tagged PC2 were plated in 60-mm dishes for 1 hr starvation in the pre-labeling medium L-methionine and L-cysteine free Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS) and penicillin/streptomycin (Invitrogen Canada). This was followed by pulse-labeling with 250 μCi of [35S]methionine/cysteine EXPRE35S Protein Labeling Mix (PerkinElmer, Woodbridge, ON, Canada) for 30 minutes (min). Cells were harvested in ice-cold CelLytic-M lysis buffer (Sigma-Aldrich Canada, Oakville, ON, Canada) supplemented with protease inhibitor cocktail (Sigma-Aldrich Canada and 500 μg total protein was used for immunoprecipitation (IP) with anti-GFP (EU4) and magnetic Dynabeads (Invitrogen Canada). The resulting precipitates were subject to SDS-PAGE and autoradiography.
Cell surface biotinylation

Cells were grown to 90% confluency in 100-mm dishes, washed with ice-cold PBS and borate buffer (10 mM boric acid, 154 mM NaCl, 7.2 mM KCl, 1.8 mM CaCl₂, pH 9.0), and then incubated with 0.5 mg/ml Pierce EZ-LinkTM Sulfo-NHS-SS-Biotin (Fisher Scientific Canada, Toronto, ON, Canada) at 4°C with agitation for 30 min. After washing with quenching buffer (192 mM glycine, 25 mM Tris, pH 8.3), cells were lysed in ice-cold Celllytic-M reagent supplemented with protease inhibitor cocktail to make 2–5 μg/μl total protein lysate. The biotinylated and flow-through intracellular proteins were separated using 50 μl of Pierce Avidin Agarose (Fisher Scientific Canada, Markham, ON, Canada) by incubation overnight at 4°C and subsequent centrifugation. After intensive washing in the NP40 buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP40) with protease inhibitor cocktail, biotinylated proteins were resuspended in the SDS sample buffer and eluted from beads by heating at 65°C for 5 min. An equal amount of biotinylated proteins and 20 μg of total and intracellular proteins were separated on 8% SDS-PAGE for IB.

Degradation analysis

Degradation assays were based on the use of protein synthesis inhibitor cycloheximide (CHX) and proteasome inhibitor MG132 (Sigma-Aldrich Canada). Equal number of cells were plated into 6-well plates, treated with CHX (50 μM in DMSO) or MG132 (10 μM in DMSO). DMSO was used as control. For CHX treatment, cells were lysed at different time points (0, 2, 4 and 8 hr). For MG132 treatment, cells were lysed at the same time points. Cells were harvested into samples with equal volume (ie equal cell number). The lysates were loaded for WB and signal density was measured by ImageJ (National Institute of Health, Bethesda, MD, USA).

Co-immunoprecipitation (co-IP)

Cells growing on 100-mm dish were harvested in 1 ml ice-cold CelLytic-M lysis buffer according to the manufacturer’s instructions. 500 μg total proteins from postnuclear supernatant were incubated with 2 μg primary antibodies at 4°C for 4 hr, followed by overnight incubation with gentle shaking upon the addition of 50 μl protein G sepharose (Thermo Fisher Scientific, Rockford, IL, USA). The precipitates absorbed to protein G sepharose were resuspended in SDS sample buffer and subjected to SDS-PAGE, followed by IB. For Ca dependent co-IP experiments, 1 mM Ca and 1 mM EGTA were added to the lysis and washing buffers.

Far Western blotting (WB)

Far WB was performed as previously described [30]. Briefly, 50 μg protein lysates from M2 and A7 cells stably expressing PC2 were separated by SDS-PAGE. After transfer onto nitrocellulose membranes, proteins were denatured, renatured and then incubated with E.coli purified GST-PC2C with or without His-FLNAC, as previously used [21]. After washing, proteins were detected with FLNA and PC2 antibody. FLNA-deficient M2 cells served as a negative control.

Data analysis

IB signals were quantified by ImageJ and data were analyzed and plotted using SigmaPlot 12 (Systat Software, San Jose, CA, USA), and expressed as mean ± SEM (N), where SEM represents the standard error of the mean and N indicates the number of experimental repeats. Paired or unpaired t-test was used to compare two sets of data. Probability values (p) of less than 0.05 and 0.01 were considered significant (*) and very significant (**), respectively.
Results

Effect of FLNA on the steady-state level of PC2

We recently reported that FLNA reduces PC2 channel activity through direct binding with both the N- and C-termini of PC2 [21]. Here we found by WB analysis that in HeLa and HEK293 cells the endogenous PC2 expression level substantially decreases in the presence of FLNA knockdown (KD) by three different siRNA pairs (Fig 1A). These data show a clear association between the PC2 and FLNA levels. A similar effect of FLNA KD was also observed in IMCD cells (data not shown). The use of the three effective FLNA siRNA pairs strongly indicates a specific effect of FLNA KD on PC2 expression. We next used human melanoma M2 cells deficient of filamins and FLNA-replete A7 cells for similar experiments. We found that the steady-state level of stably and transiently expressed GFP-PC2 in A7 cells is 64 ± 10% (N = 5; p < 0.001) and 41 ± 10% (N = 3; p < 0.001), respectively, more than that in M2 cells (Fig 1B). These data let us think that the presence of FLNA may lead to higher PC2 protein synthesis or lower PC2 protein degradation. For this we performed 35S pulse labeling in combination of co-IP with GFP antibody and magnetic Dynabeads to measure the synthesis of GFP-PC2. WB analysis did not reveal an increased GFP-PC2 protein synthesis (for 30 min) in FLNA-containing A7 cells compared with M2 cells (Fig 1C), suggesting that PC2 in A7 cells may have a lower degradation rate than in M2 cells. These data together let us reason that FLNA may have inhibited cellular PC2 degradation.

Effect of FLNA on PC2 degradation

We next examined the effect of FLNA on degradation of GFP-PC2 in A7 and M2 stable cell lines. For this, we used cycloheximide (CHX) to stop the biosynthesis and chased the PC2 expression at different time points by WB. We found that PC2 degradation is significantly slower in FLNA-containing A7 cells than in M2 cells (Fig 2A). In average, the half-life of PC2 protein in A7 cells was 4.4 ± 0.2 hr (N = 4) while that in M2 cells was only 2.3 ± 0.5 hr (N = 4). Similar results were obtained for transiently expressed GFP-PC2 in A7 cells with or without FLNA KD, ie, FLNA KD in A7 cells speeded up PC2 degradation (Fig 2B, upper panel). Interestingly, although both PC2C and PC2N bind filamins, we found that FLNA only reduces the degradation of PC2C (Fig 2B, middle panel), but not PC2N (Fig 2B, lower panel) in A7 cells. Our data together indicated that FLNA represses PC2 degradation through interaction with its C-terminus. We and other researchers previously found that PC2 undergoes proteasome degradation [31,32]. To determine whether FLNA affects the pathway through which PC2 is degraded, we utilized proteasome inhibitor MG-132 and found that incubation with MG-132 for 4 hr substantially blocks PC2 degradation in both A7 and M2 cells (Fig 2C), demonstrating that PC2 degradation is still proteasome dependent in the absence of filamin.

Effect of FLNA on the plasma membrane (PM) PC2 expression

By use of surface biotinylation, we found that more PC2 is present on the PM of A7 cells compared to M2 cells (Fig 3A). In average, surface PC2 in A7 cells increased by 1.6 ± 0.5 fold (N = 3, p = 0.01) of that in M2 cells. Because the total PC2 expression in A7 cells was only increased by 0.6 fold of that in M2 cells (Fig 1A), this result suggests that FLNA has a stronger stabilizing effect on PM PC2 than intracellular PC2. Interestingly, we detected much more FLNA in the biotinylated A7 cell lysate with PC2 over-expression than in control lysates (Fig 3B), indicating that more FLNA molecules bound with PM PC2 were pulled down under this condition. In fact, we recently reported a similar phenomenon for the scaffolding protein, receptor for activated C kinase RACK1, that interacts with surface membrane TRPP3 channel,
homolog of PC2 [33]. We next examined whether M2 cells transiently transfected with wild type FLNA mimics A7 cells in terms of regulating PM PC2. By WB and biotinylation assays we found that PM PC2 was increased in the presence of FLNA while the flow-through PC2 remained unaffected (Fig 3C). We noticed that FLNA over-expression is rather modest, possibly due to its large size, but still results in an increased PM PC2.

Effects of FLNAC on the FLNA-PC2 interaction and PC2 expression

Because PC2 binds FLNA through domain FLNAC (aa 2150–2647) [21], we next utilized FLNAC as a potential blocking peptide to explore how FLNA regulates surface membrane expression of PC2. For this we transiently transfected FLNAC into M2 and A7 cells stably expressing GFP-PC2 and performed co-IP with GFP antibody. The interaction of FLNAC with PC2 was detected in M2 and A7 cells, as expected (Fig 4A). Over-expression of FLNAC reduces the PC2-FLNA interaction in A7 cells (Fig 4B), indicating that FLNAC effectively acts as a blocking peptide. Interestingly, we also observed an interaction between FLNA and FLNAC (Fig 4B), consistent with the fact that FLNA molecules form dimers through their C-terminus [19], which together suggests the presence of complex nPC2-FLNA-FLNAC, where n indicates the number of PC2 molecules in the complex. To further document the role of FLNA and FLNAC (Fig 4B), consistent with the fact that FLNA molecules form dimers through their C-terminus [19], which together suggests the presence of complex nPC2-FLNA-FLNAC, where n indicates the number of PC2 molecules in the complex. To further document the role of FLNA as a blocking peptide in the PC2-FLNA interaction, we performed Far WB assays using A7 and M2 cells. PC2C signal was detected on the membrane at the position/size of FLNA in A7, but not in M2 cell lysate after incubating with GST-PC2C protein purified from E. coli (Fig 4C, left panel), indicating direct binding between PC2C and FLNA. Then, co-incubation of purified His-FLNAC (from E. coli as well) and purified GST-PC2C reduced the PC2C signal (Fig 4C, right panel), indicating that FLNAC competed with PC2C for binding with FLNA.

We reasoned that if the binding domain of FLNA (FLNAC) is sufficient to prevent PC2 degradation, FLNAC over-expression would prolong PC2 half life in M2 cells. On the other hand, if full-length FLNA is required to maintain the stability of PC2, then through disrupting the PC2-FLNA interaction FLNAC should destabilize PC2 in A7 cells but not in M2 cells. To test this hypothesis, we over-expressed FLNAC in A7 and M2 cells and measured the steady-state level of the PM and total PC2. FLNAC significantly reduced the PM level of PC2 (Fig 5A and 5B) in A7 cells while it had no or a very modest effect on the flow-through or total PC2 (Fig 5A, right panel, and 5C, left panel), and indeed had no effect on either the PM or total PC2 in M2 cells (Fig 5A and 5C, right panel). Further, over-expression of FLNAC in HeLa, HEK293 and IMCD cells also resulted in a decreased endogenous PC2 level (Fig 5D). These data together indicated that while full-length FLNA maintains the stability of PC2, FLNAC decreases PC2 stability through interfering with the FLNA-PC2 binding.

Role of the PC2-FLNA-actin complex in surface PC2 stabilization

Since FLNAC decreased the interaction of PC2 with full-length FLNA and seemed to have destabilized surface PC2 in A7 cells, and FLNA is a well known actin-binding protein, we reasoned that FLNA stabilizes PC2 on the cell surface through anchoring to actin filaments. To test this, we first performed co-IP assays to prove the presence of the PC2-FLNA-actin
complex. We utilized A7 GFP-PC2 stable cells, with either control (Ctrl) or FLNA KD. We found that both FLNA and β-actin were precipitated by GFP antibody (Fig 6A).
dramatically decreased the binding strength of β-actin with PC2, indicating that FLNA is an important mediator for the PC2-β-actin interaction. Furthermore, similar results were obtained using endogenous PC2 in HeLa cells with or without FLNA KD, i.e., FLNA KD much reduced the interaction strength between endogenous PC2 and β-actin (Fig 6B). Given the fact that FLNA binds directly with actin [34], our data together strongly show that PC2, FLNA and β-actin are in the same protein complex, presumably in the form of PC2-FLNA-actin. We also performed immunofluorescence assays with A7 and IMCD cells over-expressing GFP-PC2 to
Fig 4. Effect of FLNAC on the FLNA-PC2 interaction. All data are from three or more independent experiments. A, representative data from co-IP showing interaction of GFP-PC2 with FLNA and FLNAC in M2 and A7 cells. B, representative data showing the effect of blocking peptide FLNAC on the FLNA-PC2 interaction in A7 cells. C, Far WB showing the competition of FLNAC with PC2C for binding to FLNA. Lysates of M2 and A7 cells (stably expressing GFP-PC2) were separated by SDS-PAGE and transferred to nitrocellulose membrane. Proteins were denatured, renatured and then incubated with purified GST-PC2C and none (left panel) or His-FLNAC (right panel). Bound protein was detected by PC2 (H-280) antibody. The arrow (—) indicates PC2C signal detected at the site of FLNA. The star (*) indicates stably expressed GFP-PC2 signal, as a control.

doi:10.1371/journal.pone.0123018.g004
Fig 5. **Effect of FLNAC on the surface and total PC2 expression.** A, representative biotinylation data showing the effect of FLNAC on the PM (biotinylation) and intracellular (FT) GFP-PC2 expression in M2 and A7 cells. B, averaged PC2 PM expression in A7 cells showing the effect of FLNAC overexpression. FLNAC reduced PC2 PM expression to 46% ± 12% (N = 3; p < 0.001) of the control level. C, representative data showing the effect of FLNAC on the total PC2 expression in GFP-PC2 stably expressing A7 (left panel) (N = 3; p = 0.01) and M2 cells (right panel) (N = 3; p = 0.16). HSP60 was used as a loading control. D, WB data showing the effect of FLNAC on the endogenous PC2 level in HeLa (left panel), HEK293 (middle panel) and IMCD (right panel) cells detect by antibody H-280. β-actin was used as a loading control (N = 3).

doi:10.1371/journal.pone.0123018.g005
show the relative localization of PC2, FLNA and actin (Fig 6C, upper and lower panels). The PM expression of PC2 in A7 cells was also demonstrated by its colocalization with Na/K ATPase (Fig 6C, middle panel).

Next, we performed biotinylation assay to check the PC2-FLNA-β-actin complex on the cell surface. We found that in A7 cells, a larger proportion of PC2 is expressed on the cell surface compared to M2 cells (Fig 5A). And correspondingly, more β-actin was detected in the biotinylation lysate of A7 cells than M2 cells (Fig 6D), presumably due to the presence of FLNA in A7 cells. However, in M2 cells, PC2 was also able to bind β-actin at a lower strength, possibly through other interacting partners (Fig 6D). These data suggest that FLNA tethers the PM PC2 to the actin network to prevent rapid internalization as seen in M2 cells. Interestingly, FLNAC over-expression in A7 cells substantially reduced the PM localized PC2-FLNA-β-actin complex (Figs 5A and 6D), presumably because the competition between FLNAC and FLNA for binding PC2 resulted in destabilization of the complex. Thus, because FLNAC does not bind with actin [34], our data indicate that, by reducing the PC2-FLNA interaction, FLNAC prevents PC2 from anchoring to the actin filament, thereby destabilizing PM PC2 and decreasing its PM expression. In summary, these data demonstrate that FLNA stabilizes PC2 on the PM by forming PC2-FLNA-actin complex to anchor it to the actin filament.

The stabilizing effect of actin may also contribute to a higher amount of FLNAC detected in the PM PC2 precipitate in A7 cells than in M2 cells (Fig 6D). As filamin mainly exists as dimers in cells, complex nPC2-FLNAC-FLNAC would be present in M2 cells. However, this complex is unable to bind to actin due to the absence of the actin-binding domain localized on the FLNA N-terminus, it should be less stable than complex nPC2-FLNA-FLNAC in A7 cells that is able to bind to actin. Further, the fact that both the PM PC2 and total FLNAC levels in A7 cells are much higher than those in M2 cells (Figs 3A and 4A) should be another contributing factor for a higher amount of FLNAC bound to the PM PC2 in A7 cells.

Roles of Ca on the physical interaction of PC2 and FLNA

While our current study showed a stabilizer effect of FLNA on PC2 protein expression, we previously reported that FLNA inhibits PC2 cation channel activity that shows high permeability to Ca [21]. We reasoned that their physical binding should be for the purpose of (channel) functional regulation. Thus, it is possible that the FLNA-PC2 binding is to regulate the Ca entry through PC2. If this is the case, their binding may be Ca-dependent. For this we performed co-IP assays between FLNA and PC2 using HeLa cells and added a final concentration of 1 mM EGTA (to chelate Ca), 1 mM Ca, or none to the lysates. Indeed, we found that Ca chelation by EGTA substantially decreases the FLNA-PC2 binding (Fig 7A), indicating a strong Ca-dependent binding between the two proteins. No significant effect was observed for addition of 1 mM Ca, presumably because the Ca concentration in the cell lysate is already saturated for the binding between PC2 and FLNA that normally should face only sub-micromolar cytoplasmic Ca in living cells. Similar Ca dependence of the PC2-FLNA binding was observed in HEK293 and IMCD cells, but not in the presence of FLNA KD by siRNA (Fig 7B and 7C).
This Ca-dependent PC2-FLNA interaction suggests a dynamic regulation of Ca flux through PC2 by FLNA that increased intracellular Ca concentration promotes the binding of FLNA to PC2 to reduce Ca leak from the ER thereby preventing further intracellular Ca increase.

**Discussion**

Because too much or too little of PC2 is pathogenic [14,15], understanding how PC2 is regulated by cellular factors is of great importance. Recently we reported protein-protein interaction between filamin and polycystin-2 (PC2), through which filamin inhibited PC2 channel function [21]. In the current study we have demonstrated how FLNA regulates the stability and surface membrane expression of PC2 protein in human cultured cells, and how FLNA interacts with PC2 in a Ca-dependent manner. In particular, we have found that FLNA stabilizes PC2 on the cell surface by forming a protein triplex PC2-filamin-actin, and the physical interaction of PC2-FLNA are Ca-dependent.

Filamins are well known structural proteins that act as actin organizers, membrane stabilizers and scaffolds [35]. It was reported that FLNA stabilizes the surface membrane localization
and/or inhibit degradation of several target proteins such as the Ca-sensing receptor, calcitonin receptor, chloride channel CFTR, ENaC, dopamine receptor, inwardly rectifying potassium channel Kir2.1, and pacemaker channel HCN [35–41]. For example, FLNA interacts with Ca-sensing receptors in M2 and HEK cells to increase its PM and cellular levels by preventing degradation [41]. FLNA inhibits the degradation of calcitonin receptor and is critical in maintaining its normal recycling from endosomes to the surface membrane in HEK293 cells [39]. FLNA also stabilizes the PM localization of dopamine D2 receptors and potassium channel Kir2.1 but has no effect on the total expression of the receptors [37,38]. Further, FLNA is critical for podosome stabilization for macrophage mesenchymal migration [42]. FLNC may also play important roles in protein stabilization and degradation, as mutations in FLNC can cause myofibrillar myopathy characterized by disintegration of myofibrils, massive formation of protein aggregates, and altered degradation pathways within skeletal muscle fibers [43]. Thus, our current study allows adding PC2 as a novel regulation target of FLNA, in terms of PM localization and protein degradation. On the other hand, in view of similar effects of FLNA on PC2 and other membrane proteins listed above, our finding that protein complex PC2-FLNA-actin is critical for PC2 stability and prevention of degradation suggests that the “membrane protein-FLNA-actin” link may be a general way by which many membrane proteins are anchored to actin filaments and stabilized.

It has been reported that filamin links several membrane proteins to the actin cytoskeleton, such as dopamine receptors, platelet glycoprotein Ibα, β-integrin and FcγRI [37,44–46], but there has never been direct and firm demonstration as to how filamin mediates the link. In fact, most evidence came from co-IP assays showing interactions between pairs of two proteins among membrane protein, filamin and actin. However, showing interactions between all three possible pairs does not guarantee the existence of a membrane protein-filamin-actin triplex. Because of this, we carried out co-IP assays between PC2 and actin by altering the level of FLNA in A7 and HeLa cells via FLNA shRNA, and found that FLNA is critical in the complexing between PC2 and actin (Fig 6A and 6B), which demonstrated the presence of a protein triplex in the form of PC2-FLNA-actin. This was further supported by increased recruitment of actin molecules to the surface membrane when FLNA is present and is not interfered by blocking peptide FLNAC (Fig 6D).

Several studies indicated that the protein level of PC2 is critical for cell function and needs to be strictly regulated within a narrow range. Immunohistochemistry studies using staged mouse embryos indicated that PC2 expression is developmentally regulated and that this regulation is important for embryo development [47]. In adult mice, PC2 was also reported to be markedly up-regulated by renal ischaemic injury [48–50], indicating the importance of PC2 for the recovery from ischaemia. Studies of PC2-dependent ADPKD in mouse model also showed that both PC2 knock-out and knock-in mice develop typical renal cysts and an increase in cell proliferation and apoptosis, which are reflective of human ADPKD phenotypes [14,15]. However, mechanisms of how PC2 protein level is regulated are still not well understood. Generally, the steady-state protein level is defined by both synthesis and degradation. Although some transcription factors such as E2F, EGRF and SP1 were predicted by computational analyses to bind with the PKD2 promoter, little experimental data on PKD2 transcriptional regulation have been published [51]. On the translation level, it was reported that microRNA miR-17 down-regulates PC2 by binding with its 3’ untranslated region [52] and that this binding site is also recognized by the RNA-binding cystic protein bicaudal C, which antagonizes the repressive activity of miR-17 [53]. Previously, we reported that PC2 is regulated by endoplasmic reticulum associated degradation (ERAD) through the ubiquitin-proteasome system by interacting with Herp, an ubiquitin-like protein implicated in regulation of ERAD [31]. Our current study
revealed a novel mechanism by which a membrane protein can be stabilized, namely through forming protein complex PC2-FLNA-actin for anchorage to the actin filaments.

We also examined whether FLNA affects the mRNA level of PC2 in HeLa, HEK293, A7 and M2 cells by reverse transcript (RT)-PCR and real-time RT-PCR, and found that the PKD2 mRNA level is much lower in the presence of FLNA, e.g., the mRNA level in A7 cells represented only 41 ± 5% (N = 5; p < 0.001) of that in M2 cells, which roughly accounted for the observed lower synthesis (Fig 1C). The mechanism of how FLNA regulates the mRNA level of PKD2 remained to be determined by future studies. However, it was previously reported that cytoplasmic FLNA through binding with transcription factors such as PEBP2/CFB and p73α regulates the transcription of several genes including interleukin-3, T cell receptors, and cell cycle inhibitor p21 Waf1/Cip1 [54–56]. Therefore, it is possible that PKD2 gene is a downstream target of a FLNA-regulated transcription factor.

In summary, our present study found that FLNA is an important regulator of PC2 that it prevents PC2 degradation and stabilizes surface membrane PC2 through forming protein trplex PC2-FLNA-actin for anchoring to the cytoskeleton. This mechanism of stabilization may be important for cystogenesis of ADPKD. However, ADPKD renal cysts arise from different nephron segments (proximal and distal tubules) with different characteristics [57] which can’t be modeled by cultured cell lines. This should be considered when interpreting the data obtained in the present study. Our finding of PC2 stabilized by filamin and actin may also be applicable to other membrane proteins of which the stability and degradation are similarly regulated by filamin. On the other hand, FLNA binds PC2 and inhibits its channel function through direct binding [21], and the PC2-FLNA binding was found to be Ca-dependent (Fig 7). With regard to what is the net effect of FLNA, we think that when the cytoplasmic Ca concentration is high, FLNA through direct binding shuts down PC2-mediated Ca entry (from the extracellular space or ER) to avoid Ca overloading; Conversely, when Ca is low, FLNA dissociates from PC2 thereby removing the inhibition to allow Ca entry via PC2. Because the intracellular Ca concentration would frequently change in time and space filamins may still be able to maintain PC2 stability on the membrane while accomplishing its Ca-dependent binding with and functional regulation of PC2.

Acknowledgments

We thank Dr. Z. Shen (Cancer Institute of New Jersey) for providing FLNA shRNA plasmid and corresponding empty vector p/PUR/U6. QW is a recipient of the studentships from the Alberta Innovates—Health Solutions and the NSERC-CREATE International Research Training Group in Membrane Biology. The authors declare no competing interests. This work is supported by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Kidney Foundation of Canada (to XZC).

Author Contributions

Conceived and designed the experiments: QW JFT XZC. Performed the experiments: QW WZ ZCW JWY. Analyzed the data: QW SH JFT. Wrote the paper: QW ZCW JFT XZC.

References

1. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ et al. (1996) PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272: 1339–1342. PMID: 8650545
2. Cai Y, Maeda Y, Cedzich A, Torres VE, Wu G, Hayashi T et al. (1999) Identification and characterization of polycystin-2, the PKD2 gene product. J Biol Chem 274: 28557–28565. PMID: 10497221
3. Pazour GJ, San Agustin JT, Follit JA, Rosenbaum JL, Witman GB (2002) Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol 12: R378–R380. PMID:12062067
4. Barr MM, DeModena J, Braun D, Nguyen CQ, Hall DH, Stemberg PW (2001) The Caenorhabditis elegans autosomal dominant polycystic kidney disease gene homologs lov-1 and pkd-2 act in the same pathway. Curr Biol 11: 1341–1346. PMID:11553327
5. Ong AC, Ward CJ, Butler RJ, Biddolph S, Bowker C, Torra R et al. (1999) Coordinate expression of the autosomal dominant polycystic kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue. Am J Pathol 154: 1721–1729. PMID:10362797
6. Kottgen M, Benzing T, Simmen T, Tauber R, Buchholz B, Feliciangeli S et al. (2005) Trafficking of TRPP2 by PACS proteins represents a novel mechanism of ion channel regulation. EMBO J 24: 705–716. PMID:15692563
7. Miyakawa A, Ibarra C, Malmersjo S, Aperia A, Wiklund P, Uhlen P (2013) Intracellular calcium release modulates polycystin-2 trafficking. BMC Nephrol 14: 34. doi:10.1186/1471-2369-14-34 PMID:23398808
8. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X et al. (2003) Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33: 129–137. PMID:12514735
9. Rundle DR, Gorbsky G, Tsiokas L (2004) PKD2 interacts and co-localizes with mDia1 to mitotic spindles of dividing cells: role of mDia1 IN PKD2 localization to mitotic spindles. J Biol Chem 279: 29728–29739. PMID:15123714
10. Wilson PD, Schrier RW, Breckon RD, Gabow PA (1986) A new method for studying human polycystic kidney disease epithelia in culture. Kidney Int 30: 371–378. PMID:2431189
11. Lanoix J, D'Agati V, Szabolcs M, Trudel M (1996) Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 13: 1153–1160. PMID:880689
12. Ibraghimov-Beskrovnaya O Bukanov NO (2006) In vitro cystogenesis: the search for drugs antagonizing cyst development. Nephrol Ther 2 Suppl 2:S109–14.: S109-S114. PMID:17373209
13. Liang G, Yang J, Wang Z, Li Q, Tang Y, Chen XZ (2008) Polycystin-2 down-regulates cell proliferation via promoting PERK-dependent phosphorylation of eIF2alpha. Hum Mol Genet 17: 3254–3262. doi:10.1093/hmg/ddn221 PMID:18664456
14. Park EY, Sung YH, Yang MH, Noh JY, Park SY, Lee TY et al. (2009) Cyst formation in kidney via B-Raf signalling in the PKD2 transgenic mice. J Biol Chem 284: 7214–7222. doi:10.1074/jbc.M805890200 PMID:19098310
15. Wu G, D'Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM et al. (1998) Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93: 177–188. PMID:9568711
16. Hartwig JH Stossel TP (1975) Isolation and properties of actin, myosin, and a new actinbinding protein in rabbit alveolar macrophages. J Biol Chem 250: 5696–5705. PMID:124734
17. Stossel TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M et al. (2001) Filamins as integrators of cell mechanics and signalling. Nat Rev Mol Cell Biol 2: 138–145. PMID:11252955
18. van der FA Sonnenberg A (2001) Structural and functional aspects of filamins. Biochim Biophys Acta 1538: 99–117. PMID:11336782
19. Gorlin JB, Yamin R, Egan S, Stewart M, Stossel TP, Kwiatkowski DJ et al. (1990) Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): a molecular leaf spring. J Cell Biol 111: 1089–1105. PMID:2391361
20. Deng W, Lopez-Camacho C, Tang JY, Mendoza-Villanueva D, Maya-Mendoza A, Jackson DA et al. (2012) Cytoskeletal protein filamin A is a nucleolar protein that suppresses ribosomal RNA gene transcription. Proc Natl Acad Sci U S A 109: 1524–1529. doi:10.1073/pnas.1107879109 PMID:22907607
21. Wang Q, Dai XQ, Li Q, Wang Z, Cantero MR, Li S et al. (2012) Structural interaction and functional regulation of polycystin-2 by filamin. PLoS One 7: e40448. doi:10.1371/journal.pone.0040448 PMID:22892962
22. de Wit MC, Kros JM, Halley DJ, de C I, Verdijk R, Jacobs BC et al. (2009) Filamin A mutation, a common cause for ventriculocerebral heterotopia, aneurysms and cardiac defects. J Neurol Neurosurg Psychiatry 80: 426–428. doi:10.1136/jnnp.2008.149419 PMID:19289478
23. Pilop C, Aregger F, Gorman RC, Brunisholz R, Germs B, Schaffner T et al. (2009) Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms. Circulation 120: 983–991. doi:10.1161/CIRCULATIONAHA.108.843516 PMID:19720936
24. Feng Y Walsh CA (2004) The many faces of filamin: a versatile molecular scaffold for cell motility and signalling. Nat Cell Biol 6: 1034–1038. PMID:15516996
25. Chen XZ, Li Q, Wu Y, Liang G, Lara CJ, Cantiello HF (2008) Submembraneous microtubule cytoskeleton: interaction of TRPP2 with the cell cytoskeleton. FEBS J 275: 4675–4683. doi: 10.1111/j.1742-4658.2008.06616.x PMID: 18754774

26. Li Q, Montalbetti N, Shen PY, Dai XQ, Cheeseman CI, Karpinski E et al. (2005) Alpha-actinin associates with polycystin-2 and regulates its channel activity. Hum Mol Genet 14: 1587–1603. PMID: 15843396

27. Gonzalez-Perrett S, Kim K, Ibarra C, Damiano AE, Zotta E, Batelli M et al. (2001) Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel. Proc Natl Acad Sci U S A 98: 1182–1187. PMID: 11252306

28. Montalbetti N, Li Q, Gonzalez-Perrett S, Semprine J, Chen XZ, Cantiello HF (2005) Effect of hydro-osmotic pressure on polycystin-2 channel function in the human syncytiotrophoblast. Pflugers Arch 451: 294–303. PMID: 16025301

29. Wu Y, Dai XQ, Li Q, Chen CX, Mai W, Hussain Z et al. (2006) Kinesin-2 mediates physical and functional interactions between polycystin-2 and fibrocystin. Hum Mol Genet 15: 3280–3292. PMID: 17008358

30. Wu Y, Li Q, Chen XZ (2007) Detecting protein-protein interactions by Far western blotting. Nat Protoc 2: 3278–3284. PMID: 18079728

31. Liang G, Li Q, Tang Y, Kokame K, Kikuchi T, Wu G et al. (2008) Polycystin-2 is regulated by endoplasmic reticulum-associated degradation. Hum Mol Genet 17: 1109–1119. doi: 10.1093/hmg/ddm383 PMID: 18178578

32. Tian Y, Kolb R, Hong JH, Carroll J, Li D, You J et al. (2007) TAZ promotes PC2 degradation through a SCFBeta-Trcp E3 ligase complex. Mol Cell Biol 27: 6383–6395. PMID: 17636028

33. Yang J, Wang Q, Zheng W, Tuli J, Li Q, Wu Y et al. (2012) Receptor for activated C kinase 1 (RACK1) inhibits function of transient receptor potential (TRP)-type channel Pkd2L1 through physical interaction. J Biol Chem 287: 6551–6561. doi: 10.1074/jbc.M111.305854 PMID: 22174419

34. Popowicz GM, Schleicher M, Noegel AA, Holak TA (2006) Filamins: promiscuous organizers of the cytoskeleton. Trends Biochem Sci 31: 411–419. PMID: 16781869

35. Lin R, Karpa K, Kabbani N, Goldman-Rakic P, Levenson R (2001) Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc Natl Acad Sci U S A 98: 5258–5263. PMID: 11320256

36. Sampson LJ, Leyland ML, Dart C (2003) Direct interaction between the actin-binding protein filamin-A and the inwardly rectifying potassium channel, Kir2.1. J Biol Chem 278: 41988–41997. PMID: 12923176

37. Seck T, Baron R, Horne WC (2003) Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling. J Biol Chem 278: 10408–10416. PMID: 12531889

38. Wang Q, Dai XQ, Li Q, Tuli J, Liang G, Li SS et al. (2013) Filamin interacts with epithelial sodium channel and inhibits its channel function. J Biol Chem 288: 264–273. doi: 10.1074/jbc.M112.396408 PMID: 23161538

39. Zhang M, Breitwieser GE (2005) High affinity interaction with filamin A protects against calcium-sensing receptor degradation. J Biol Chem 280: 11140–11146. PMID: 15670611

40. Guiet R, Verollet C, Lamsoul I, Cougoule C, Poincloux R, Labrousse A et al. (2012) Macrophage mesenchymal migration requires podosome stabilization by filamin A. J Biol Chem 287: 13051–13062. doi: 10.1074/jbc.M112.396408 PMID: 23161538

41. Kley RA, van d V, Olive M, Hoffeld J, Goldfarb LG, Furst DO et al. (2013) Impairment of protein degradation in myofibrillar myopathy caused by FLNC/filamin C mutations. Autophagy 9: 422–423. doi: 10.4161/auto.22921 PMID: 23234888

42. Beekman JM, van der Poel CE, van der Linden JA, van den Berg DL, van den Bergh PV, van de Winkel JG et al. (2008) Filamin A stabilizes Fc gamma RI surface expression and prevents its lysosomal routing. J Immunol 180: 3938–3945. PMID: 18322202

43. Calderwood DA, Huttonlocher A, Kissoses WB, Rose DM, Woodside DG, Schwartz MA et al. (2001) Increased filamin binding to beta-integrin cytoplasmic domains inhibits cell migration. Nat Cell Biol 3: 1060–1068. PMID: 11781567

44. Yuan Y, Zhang W, Yan R, Liao Y, Zhao L, Ruan C et al. (2009) Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating...
Filamin-A Stabilizes Polycystin-2

47. Markowitz GS, Cai Y, Li L, Wu G, Ward LC, Somlo S et al. (1999) Polycystin-2 expression is developmentally regulated. Am J Physiol 277: F17–F25. PMID: 10409293

48. Prasad S, McDaid JP, Tam FW, Haylor JL, Ong AC (2009) Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury. Am J Pathol 175: 1493–1503. doi: 10.2353/ajpath.2009.090227 PMID: 19729489

49. Zhao Y, Haylor JL, Ong AC (2002) Polycystin-2 expression is increased following experimental ischemic renal injury. Nephrol Dial Transplant 17: 2138–2144. PMID: 12454224

50. Obermuller N, Cai Y, Kranzlin B, Thomson RB, Gretz N, Kriz W et al. (2002) Altered expression pattern of polycystin-2 in acute and chronic renal tubular diseases. J Am Soc Nephrol 13: 1855–1864. PMID: 12089381

51. Lantinga-van L, I, Leonhard WN, Dauwerse H, Baelde HJ, van Oost BA, Breuning MH et al. (2005) Common regulatory elements in the polycystic kidney disease 1 and 2 promoter regions. Eur J Hum Genet 13: 649–659. PMID: 15770226

52. Sun H, Li OW, Lv XY, Ai JZ, Yang QT, Duan JJ et al. (2010) MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation. Mol Biol Rep 37: 2951–2958. doi: 10.1007/s11033-009-9861-3 PMID: 19821056

53. Tran U, Zakin L, Schweickert A, Agrawal R, Doger R, Blum M et al. (2010) The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity. Development 137: 1107–1116. doi: 10.1242/dev.046045 PMID: 20215348

54. Yoshida N, Ogata T, Tanabe K, Li S, Nakazato M, Kohu K et al. (2005) Filamin A-bound PEBP2beta/CBFbeta is retained in the cytoplasm and prevented from functioning as a partner of the RunX1 transcription factor. Mol Cell Biol 25: 1003–1012. PMID: 15657428

55. Kim EJ, Park JS, Um SJ (2007) Filamin A negatively regulates the transcriptional activity of p73alpha in the cytoplasm. Biochem Biophys Res Commun 362: 1101–1106. PMID: 17825253

56. Zhou AX, Hartwig JH, Akurek LM (2010) Filamins in cell signaling, transcription and organ development. Trends Cell Biol 20: 113–123. doi: 10.1016/j.tcb.2009.12.001 PMID: 20061151

57. Perrone RD (1985) In vitro function of cyst epithelium from human polycystic kidney. J Clin Invest 76: 1689–1691. PMID: 4095045